Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Key Takeaways The PIVOT-PO trial was stopped early after meeting its primary end point of noninferiority to imipenem-cilastatin in treating cUTI. No new safety concerns were identified, with diarrhea ...

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Significant disparities in Altmetric Attention Scores and citation rates between women and men first/last authors in oncology were reported in a recent study in JCO Oncology Practice. 1 In a recent ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

The CAPItello-280 trial was terminated due to unlikely achievement of primary endpoints in metastatic castration-resistant prostate cancer. Capivasertib, an ATP-competitive AKT inhibitor, showed a ...